Westlake Frequent-sampling Cohort 2

NCT07606885 | Recruiting

• 1 other identifier: 20260420ZJS001
• Study Type: observational
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

This observational follow-up study extends a previously completed 15-day intensive longitudinal study (WeF) of the gut microbiome in healthy adults. The objective of WeF2 is to characterize the long-term stability and dynamics of the gut and oral microbiota in the same cohort across multiple timescales, and to determine whether the day-to-day variability patterns observed at baseline persist over months and years. Participants who completed the WeF baseline protocol will be invited to attend periodic follow-up visits for low-frequency biospecimen collection and to repeat the original 15-day high-frequency sampling protocol at planned intervals, beginning approximately six months after the WeF baseline and continuing at extended intervals thereafter. By combining sparse routine sampling with recurring high-density sampling windows, the study aims to distinguish the stable core microbiome from transient and seasonal fluctuations, to track gradual community shifts under free-living conditions, and to further explore relationships among microbiome dynamics, dietary intake, and host glycemic regulation over an extended observation period.

Conditions

Health Adults; Stability of Microbiome

Keywords

Microbiome

Outcome Measures

Primary Outcomes (1)

• Gut microbiome

  Description: Using qPCR, metagenomics, metabolomics, proteomics, and culturomics, we quantified the composition and absolute abundance of the gut microbiota and characterized its short-term and long-term dynamics.

  3 years

Eligibility Criteria

• Age: 18 Years - 40 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Healthy young adults residing in Hangzhou

You may qualify if:

• Participants reside in Hangzhou

You may not qualify if:

• Refusing or unable to give informed consent
• Participants with chronic gastrointestinal diseases and take daily relevant medications
• Participants with metabolic diseases including diabetes, hypertension and cardiovascular diseases (CVD)
• Participants with craniocerebral trauma, cancer, liver disease, kidney disease, or other critical illness, or history of operation or medication
• Participants with bulimia nervosa, post-traumatic stress disorder (PTSD), chronic anxiety and depression or other critical neuronal disorder or history of relevant medication
• Being or to be pregnant or lactating.
• Participants with history of alcohol or drug addiction, or smoke above 15 cigarettes per day
• Concurrently participating other clinical trials.

Sponsors & Collaborators

• Westlake University: lead

Study Sites (1)

Westlake University

Hangzhou, Zhejiang, 310024, China

RECRUITING

Study Officials

• Ju-Sheng Zheng, PhD

  Westlake University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Ju-Sheng Zheng, PhD

CONTACT

86-0571-86915303; zhengjusheng@westlake.edu.cn

Jiang-Hua Zhang, Bachelor

CONTACT

86-18258119536; zhangjianghua@westlake.edu.cn

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 19, 2026
• First Posted: May 26, 2026
• Study Start: May 8, 2026
• Primary Completion (Estimated): May 8, 2027
• Study Completion (Estimated): December 31, 2030
• Last Updated: May 26, 2026

Record last verified: 2026-04

Locations

CN (1)